These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12621502)

  • 21. A stromal-free, serum-free system to expand ex vivo hematopoietic stem cells from mobilized peripheral blood of patients with hematologic malignancies and healthy donors.
    Yao CL; Hsu SC; Hwang SM; Lee WC; Chiou TJ
    Cytotherapy; 2013 Sep; 15(9):1126-35. PubMed ID: 23768928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.
    Körbling M; Reuben JM; Gao H; Lee BN; Harris DM; Cogdell D; Giralt SA; Khouri IF; Saliba RM; Champlin RE; Zhang W; Estrov Z
    Transfusion; 2006 Oct; 46(10):1795-802. PubMed ID: 17002637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells.
    Kobari L; Giarratana MC; Pflumio F; Izac B; Coulombel L; Douay L
    J Hematother Stem Cell Res; 2001 Apr; 10(2):273-81. PubMed ID: 11359674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.
    Chen BP; Fraser C; Reading C; Murray L; Uchida N; Galy A; Sasaki D; Tricot G; Jagannath S; Barlogie B
    Leukemia; 1995 Oct; 9 Suppl 1():S17-25. PubMed ID: 7475307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stem cell-like human endothelial progenitors show enhanced colony-forming capacity after brief sevoflurane exposure: preconditioning of angiogenic cells by volatile anesthetics.
    Lucchinetti E; Zeisberger SM; Baruscotti I; Wacker J; Feng J; Zaugg K; Dubey R; Zisch AH; Zaugg M
    Anesth Analg; 2009 Oct; 109(4):1117-26. PubMed ID: 19762739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
    Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
    Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133(+) cells.
    Yao CL; Feng YH; Lin XZ; Chu IM; Hsieh TB; Hwang SM
    Stem Cells Dev; 2006 Feb; 15(1):70-8. PubMed ID: 16522164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days.
    de Kreuk AM; Jonkhoff AR; Zevenbergen A; Hendriks EC; Schuurhuis GJ; Ossenkoppele GJ; Dräger AM; van Oostveen JW; Huijgens PC
    Bone Marrow Transplant; 2001 Jul; 28(2):145-55. PubMed ID: 11509932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice.
    Gothot A; van der Loo JC; Clapp DW; Srour EF
    Blood; 1998 Oct; 92(8):2641-9. PubMed ID: 9763545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The late dividing population of gamma-retroviral vector transduced human mobilized peripheral blood progenitor cells contributes most to gene-marked cell engraftment in nonobese diabetic/severe combined immunodeficient mice.
    Brenner S; Ryser MF; Whiting-Theobald NL; Gentsch M; Linton GF; Malech HL
    Stem Cells; 2007 Jul; 25(7):1807-13. PubMed ID: 17464090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid differentiation and maturation of SCF+IL-3+IL-11 expanded AC133+/CD34+ cells selected from high-risk breast cancer patients.
    Filip S; Vávrová J; Vokurková D; Bláha M; Vanásek J
    Neoplasma; 2000; 47(2):73-80. PubMed ID: 10985471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting.
    Jaime-Pérez JC; Hernández-Alcántara AE; Méndez-Ramírez N; Vázquez-Garza E; Cantú-Rodríguez OG; Gómez-Almaguer D
    Transfusion; 2009 Mar; 49(3):532-5. PubMed ID: 19243545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo expansion of G-CSF-mobilized peripheral blood CD133+ progenitor cells on coculture with human stromal cells.
    Kawano Y; Kobune M; Chiba H; Nakamura K; Takimoto R; Takada K; Ito Y; Kato J; Hamada H; Niitsu Y
    Exp Hematol; 2006 Feb; 34(2):150-8. PubMed ID: 16459183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.